Non‐Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First‐in‐Human Dose Selection for CNTO 5825, an Anti‐Interleukin‐13 Monoclonal Antibody

Publisher： John Wiley & Sons Inc

E-ISSN： 1742-7843|117|4|219-225

ISSN： 1742-7835

Source： BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol.117, Iss.4, 2015-10, pp. : 219-225

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 5, 2015-05 ,pp. : 743-754

John Wiley & Sons Inc

Access to resources Recommend Favorite

A first‐in‐human pharmacodynamic and pharmacokinetic study of a fully human anti‐glucagon receptor monoclonal antibody in normal healthy volunteers

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 283-291

John Wiley & Sons Inc

Access to resources Recommend Favorite

Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1537-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV‐1 human monoclonal antibody VRC01 in healthy adults

By  

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 182, Iss. 3, 2015-12 ,pp. : 289-301

John Wiley & Sons Inc

Access to resources Recommend Favorite

UGT2B17 Genetic Polymorphisms Dramatically Affect the Pharmacokinetics of MK‐7246 in Healthy Subjects in a First‐in‐Human Study

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 1, 2012-07 ,pp. : 96-102

John Wiley & Sons Inc

Access to resources Recommend Favorite